Press Releases

View: All Categories General Releases Financial Releases Year: All Years 2012 2011 2010 2009 2008 2007 2006 2005 2004 All Releases Oncothyreon Announces Promotion of Diana Hausman, M.D., to Chief Medical Officer Jan 5, 2012 9.4 KB   SEATTLE, WA, Jan. 5, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the promotion of Diana Hausman, M.D., to Chief Medical Officer.  Dr. Hausman joined Oncothyreon in August 2009 as Vice President, Clinical Development. "Diana has been instrumental in the advancement of our oncology pipeline, particul... Read more Oncothyreon Files Investigational New Drug Application for ONT-10 Dec 20, 2011 11.5 KB   SEATTLE, WA, Dec. 20, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1. Upon completion of the FDA's review of the IND, Oncothyreon expe... Read more Oncothyreon to Present at Oppenheimer Healthcare Conference Dec 7, 2011 9.1 KB   SEATTLE, WA, Dec. 7, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will be presenting at the Oppenheimer 22nd Annual Healthcare Conference in New York on Wednesday, December 14, 2011 at 2:45 p.m. Eastern Standard Time. A live and archived ... Read more Oncothyreon Presents Data from Phase 1/2 Trials of PX-866 in Combination with Docetaxel and with Cetuximab at 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Nov 13, 2011 16.6 KB   SEATTLE, Nov. 13, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the presentation of data from two Phase 1/2 trials of PX-866, an irreversible, pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco... Read more Oncothyreon Reports Third Quarter 2011 Financial Results Nov 8, 2011 23.4 KB   Company to Hold Conference Call at 4:30 p.m. EST Today SEATTLE, Nov. 8, 2011 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the third quarter ending September 30, 2011. Net loss from operations increased to $6.4 million in the third quarter of 2011 from $4.3 million in the third... Read more Oncothyreon to Present at Lazard Capital Markets Healthcare Conference Nov 8, 2011 9.0 KB   SEATTLE, WA, Nov. 8, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the company will be presenting at the Lazard Capital Markets 8th Annual Healthcare Conference in New York on Tuesday, November 15, 2011 at 9:30 a.m. Eastern Standard Time. A live and archived webcast of the presentation will be accessible by visiting... Read more Oncothyreon Announces Third Quarter 2011 Financial Results Conference Call Nov 1, 2011 9.2 KB   SEATTLE, WA, Nov. 1, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call to discuss its third quarter 2011 financial results and provide a review of its pipeline of products in development on Tuesday, November 8, 2011 at 4:30 p.m. Eastern Standard Time. To participate... Read more Oncothyreon Advances to Phase 2 Portion of Phase 1/2 Trial of PX-866 in Combination with Docetaxel Oct 20, 2011 13.7 KB   SEATTLE, WA, Oct. 20, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced it has initiated the Phase 2 portion of  its ongoing Phase 1/2 trial of PX-866 in combination with the chemotherapeutic agent docetaxel (Taxotere®) following successful completion of the Phase 1 dose escalation portion of the study. PX-866... Read more Chris Henney Receives 2011 Hall of Fame Award at Annual Biotech CEO Meeting at Laguna Beach Oct 17, 2011 9.2 KB   SEATTLE, Oct. 17, 2011 /PRNewswire/ - Christopher Henney, Chairman of the Board of Oncothyreon Inc. (Nasdaq: ONTY) and of Anthera Pharmaceuticals (Nasdaq: ANTH) and Vice Chairman of the Board of Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), received this year's Hall of Fame - special recognition of outstanding individual contributi... Read more Oncothyreon to Present at BioCentury NewsMakers in the Biotech Industry Conference Oct 17, 2011 9.0 KB   SEATTLE, WA, Oct. 17, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the company will be presenting at the BioCentury NewsMakers in the Biotech Industry Conference in New York on Friday, October 21, 2011 at 8:30 a.m. Eastern time. A live and archived webcast of the presentation will be accessible by visiting the Onco... Read more Oncothyreon Initiates Phase 2 Trial of its PI-3 Kinase Inhibitor PX-866 in Patients with Prostate Cancer Sep 12, 2011 13.9 KB   SEATTLE, WA, Sept. 12, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (... Read more Oncothyreon Obtains Anti-Bcl-2 Compound from Sanford-Burnham Medical Research Institute; License Will Expand Oncology Product Development Pipeline Sep 12, 2011 14.0 KB   SEATTLE, WA and LA JOLLA, CA, Sept. 12, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) and Sanford-Burnham Medical Research Institute (Sanford-Burnham) today announced that they have entered into an exclusive licensing agreement for sabutoclax and related compounds. Sabutoclax is a pan-inhibitor of the Bcl-2 family of anti-apop... Read more Oncothyreon Announces Presentations at Upcoming Investment Conferences in September 2011 Sep 1, 2011 9.2 KB   SEATTLE, WA, Sept. 1, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the company will be presenting at the following upcoming investment conferences in September. Stifel Nicolaus Healthcare Conference 2011 Friday, Sept... Read more Oncothyreon to Present at Wedbush Securities 2011 Life Sciences Management Access Conference Aug 9, 2011 9.1 KB   SEATTLE, WA, Aug. 9, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Julie Eastland, Chief Financial Officer and Vice President, Corporate Development, will present at the Wedbush Securities 2011 Life Sciences Management Access Conference in New York on Tuesday, August 16, 2011, at 11:10 a.m. Eastern Time. ... Read more Oncothyreon Reports Second Quarter 2011 Financial Results Aug 8, 2011 22.0 KB   Company to Hold Conference Call at 4:30 p.m. EDT Today SEATTLE, Aug. 8, 2011 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the second quarter ending June 30, 2011. Net loss from operations increased to $5.8 million in the second quarter of 2011 from $4.7 million in the second quart... Read more Oncothyreon Announces Second Quarter 2011 Financial Results Conference Call Aug 1, 2011 9.2 KB   SEATTLE, WA, Aug. 1, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call to discuss its second quarter 2011 financial results and provide a review of its pipeline of products in development on Monday, August 8, 2011 at 4:30 p.m. Eastern time. To participate in the cal... Read more Oncothyreon to Present at Jefferies 2011 Global Healthcare Conference May 31, 2011 9.0 KB   SEATTLE, May 31, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Jefferies 2011 Global Healthcare Conference in New York on Monday, June 6, 2011, at 8:30 a.m. Eastern Time. A live and archived webcast of Dr. Kirkman's pre... Read more Oncothyreon Advances to Phase 2 Portion of Phase 1/2 Trial of PX-866 in Combination with Cetuximab May 24, 2011 14.0 KB   SEATTLE, WA, May 24, 2011 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced it has initiated the Phase 2 portion of  its ongoing Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®) following successful completion of the Phase 1 dose escalation portion of the study. PX... Read more ONCOTHYREON REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS May 6, 2011 19.8 KB   COMPANY TO HOLD CONFERENCE CALL AT 4:30 P.M. EDT TODAY SEATTLE, WA, May 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported financial results for the first quarter ending March 31, 2011. Net loss from operations increased to $5.9 million in the first quarter of 2011 from $5.4 million in the first ... Read more Oncothyreon Announces First Quarter 2011 Financial Results Conference Call Today, May 6, 2011 at 4:30 p.m. Eastern May 6, 2011 9.2 KB   SEATTLE, May 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that it will conduct a conference call to discuss its first quarter 2011 financial results and provide a review of its pipeline of products in development on Friday, May 6, 2011 at 4:30 p.m. Eastern time. To participate in the call by tele... Read more Showing 1-20 of 223 Page: 1 2 3 ... 12  Next 20 = add release to Briefcase return to top ^